

Tandem C-N Coupling/Boulton-Katritzky Rearrangement Reactions of 3-Aminoisoxazoles or 1,2,4-Oxadiazol-3-amines with 2-Pyridyl Trifluoromethanesulfonate: A Rapid Access to [1,2,4]Triazolo[1,5-*a*]pyridines

Huilan Xiong, Zihao Li, Huang Tang, Lei He and Wei Zhou*

College of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510632, P. R. China.

E-mail: weizhou88@jnu.edu.cn

Supporting Information


Table of Contents

I. General Remarks	S2
II. General procedure for the tandem C-N coupling/Boulton-Katritzky rearrangement reaction.....	S2
III. Synthesis of bioactive molecular 6.....	S3
IV. NMR data for 3, 5, 6 and 7.....	S4
V. NMR Spectra for 3, 5, 6, and 7.....	S11

I. General Remarks

¹H NMR chemical shifts are reported in ppm with the CDCl₃ at 7.26 ppm or DMSO-*d*₆ at 2.50 ppm as standard. The ¹³C NMR chemical shifts were given using CDCl₃ or DMSO-*d*₆ as the internal standard (CDCl₃: δ = 77.2 ppm, DMSO-*d*₆: δ = 39.5 ppm). Coupling constants, *J*, were reported in hertz unit (Hz). High resolution mass spectra (HRMS) were obtained on a Q-STAR Elite ESI-LC-MS/MS Spectrometer. Chemical names were generated using Cambridge Soft. ChemDraw Ultra 16.0. Commercially obtained reagents were used without further purification.

II. General procedure for the tandem C-N coupling/Boulton-Katritzky rearrangement reaction




Under N₂, 1,2,4-oxadiazol-3-amines or 3-aminoisoxazoles (0.2 mmol), 2-pyridyl trifluoromethanesulfonate (0.22 mmol), Pd₂(dba)₃ (0.005 mmol), Xantphos (0.01 mmol), *t*BuOLi (0.4 mmol) and dry toluene (2.0 mL) were added to an oven-dried 15 mL Schlenk tube equipped with a stir bar were added. The tube was sealed and the reaction was stirred for 12 h at 90 °C with an oil bath. The reaction mixture was cooled to room temperature and diluted with CH₂Cl₂ (10 mL) and filtered through a short pad silica gel washing with CH₂Cl₂ (20 mL). The filtrate was concentrated and then purified by column chromatography on silica gel (PE/EA) to yield the desired products.

3-Amino-5-aryl-1,2,4-oxadiazoles^[1-2] were synthesized according to the known procedures and their NMR data were in agreement with those described in the literature. Unless noted, all of the other substrates were commercially available.


[1] K. Lu, L. Duan, B. Xu, W. Yin, D. Wu, Y. Zhao and P. Gong, Facile synthesis of 3-amino-5-aryl -1,2,4-oxadiazoles via PIDA-mediated intramolecular oxidative cyclization, *RSC Adv.*, **2016**, 6, 54277.

[2] A. M. Polozov, G. Hategan, H. Cao, A. S. Kiselyov, W. Zeller, J. Singh, A general approach to indole-7-yl derivatives of isoxazole, oxadiazole, thiadiazole and pyrazole, *Tetrahedron Lett.*, **2010**, 51, 575.

III. Synthesis of bioactive molecular 6



Under N_2 , **3ak** (0.2 mmol), (3-methylphenyl)boronic acid (0.40 mmol), $\text{Pd}(\text{OAc})_2$ (0.001 mmol), PPh_3 (0.002 mmol), Cs_2CO_3 (0.4 mmol) and dioxane (2.0 mL) were added to a 15 mL Schlenk tube equipped with a stir bar were added. The tube was sealed and the reaction was stirred for 12 h at room temperature. The reaction mixture was then diluted with CH_2Cl_2 (10 mL) and filtered through a short pad silica gel washing with CH_2Cl_2 (20 mL). The filtrate was concentrated and then purified by column chromatography on silica gel (PE/EA) to yield the desired product **5** in 86% yield.




To a magnetically stirred solution of compound **5** (0.2 mmol) in MeOH (5.0 mL) was added 1 M HCl solution (1 mL), and the resulting mixture was refluxed for 4h. After completion, the reaction mixture was neutralized by sat. NaHCO_3 (aq.) and the aqueous layer was extracted with CH_2Cl_2 (3 x 5 mL), the combined organic layers were washed by brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The crude product was used directly for the next step.

To a solution of the above residue in dry CH_2Cl_2 (10 mL) was added Et_3N (0.3 mmol) and followed by the addition of cyclopentylpropionyl chloride (0.25 mmol) at 0 °C under argon atmosphere. The resulting mixture was stirred for 15 min, and then then quenched by sat. NH_4Cl (aq.) (5 mL). The aqueous layer was extracted with CH_2Cl_2 (3 x 5 mL), the combined organic layers were washed by brine, dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by flash chromatography to furnish the product **6** as a white solid in 67% yield for two steps.


IV. NMR data for 3, 5, 6, 7

1-([1,2,4]triazolo[1,5-a]pyridin-2-yl)-3,3-dimethylbutan-2-one (3a)




33.5 mg, 78%, white solid, m. p. 46-48 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.51 (d, J = 8.0 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.48-7.44 (m, 1H), 6.97-6.94 (m, 1H), 4.16 (s, 2H), 1.26 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 210.2, 161.4, 151.2, 129.3, 128.1, 116.2, 113.3, 44.6, 37.2, 26.3; HRMS (ESI) calcd for $\text{C}_{12}\text{H}_{16}\text{N}_3\text{O}$ ($\text{M}+\text{H}$) $^+$ 218.1288, found 218.1289.

1-([1,2,4]triazolo[1,5-a]pyridin-2-yl)propan-2-one (3b)




22.8 mg, 65%, colorless oil; ^1H NMR (400 MHz, CDCl_3) δ 8.55 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 12.0 Hz, 1H), 7.54-7.50 (m, 1H), 7.04-7.00 (m, 1H), 4.06 (s, 2H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 203.3, 160.8, 151.4, 129.6, 128.2, 116.3, 113.6, 44.0, 29.8; HRMS (ESI) calcd for $\text{C}_9\text{H}_{10}\text{N}_3\text{O}$ ($\text{M}+\text{H}$) $^+$ 176.0819, found 176.0819.

2-([1,2,4]triazolo[1,5-a]pyridin-2-yl)-1-phenylethan-1-one (3c)




26.8 mg, 57%, colorless oil; ^1H NMR (400 MHz, CDCl_3) δ 8.54 (d, J = 8.0 Hz, 1H), 8.10 (d, J = 8.0 Hz, 2H), 7.70 (d, J = 8.0 Hz, 1H), 7.60-7.56 (m, 1H), 7.52-7.46 (m, 3H), 7.01-6.98 (m, 1H), 4.63 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 194.8, 161.2, 151.4, 136.3, 133.4, 129.5, 128.7, 128.3, 116.4, 113.5, 42.7, 39.5; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{12}\text{N}_3\text{O}$ ($\text{M}+\text{H}$) $^+$ 238.0975, found 238.0974.

3,3-dimethyl-1-(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)butan-2-one (3d)




36.8 mg, 80%, white solid, m. p. 62-65 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.39 (d, J = 8.0 Hz, 1H), 7.44 (s, 1H), 6.80 (dd, J = 6.8, 1.2 Hz, 1H), 4.15 (s, 2H), 2.48 (s, 3H), 1.28 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 210.3, 161.4, 151.6, 140.9, 127.1, 115.8, 114.9, 44.6, 37.3, 26.4, 21.5; HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{18}\text{N}_3\text{O}$ ($\text{M}+\text{H}$) $^+$ 232.1445, found 232.1444.

1-(7-chloro-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-3,3-dimethylbutan-2-one (3e)




35.6 mg, 71%, yellow solid, m. p. 54-56 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.45 (d, *J* = 8.0 Hz, 1H), 7.69 (d, *J* = 2.0 Hz, 1H), 6.98 (dd, *J* = 7.2, 2.0 Hz, 1H), 4.16 (s, 2H), 1.28 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 210.1, 162.7, 151.5, 136.2, 128.3, 115.4, 115.0, 44.7, 37.2, 26.4; HRMS (ESI) calcd for C₁₂H₁₅ClN₃O (M+H)⁺ 252.0899, found 252.0899.

3,3-dimethyl-1-(7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)butan-2-one (3f)




45.0 mg, 79%, white solid, m. p. 79-82 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.67 (d, *J* = 8.0 Hz, 1H), 8.01 (s, 1H), 7.20 (dd, *J* = 7.2, 1.2 Hz, 1H), 4.22 (s, 2H), 1.29 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 209.9, 163.4, 150.2, 131.6 (q, *J* = 34.0 Hz), 122.6 (q, *J* = 271.0 Hz), 114.2 (q, *J* = 15.0 Hz), 109.4 (q, *J* = 3.0 Hz), 44.7, 37.2, 26.3; HRMS (ESI) calcd for C₁₃H₁₅F₃N₃O (M+H)⁺ 286.1162, found 286.1160.

3,3-dimethyl-1-(6-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)butan-2-one (3g)




35.4 mg, 77%, yellow solid, m. p. 71-73 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.27 (s, 1H), 7.53 (d, *J* = 12.0 Hz, 1H), 7.29-7.27 (m, 1H), 4.12 (s, 2H), 2.34 (s, 3H), 1.23 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 210.2, 160.9, 149.8, 132.1, 126.02, 123.3, 115.3, 44.5, 37.1, 26.3, 17.8; HRMS (ESI) calcd for C₁₃H₁₈N₃O (M+H)⁺ 232.1445, found 232.1444.

1-(6-chloro-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-3,3-dimethylbutan-2-one (3h)




34.5 mg, 69%, yellow solid, m. p. 70-83 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.57 (s, 1H), 7.62 (d, *J* = 12.0 Hz, 1H), 7.45 (dd, *J* = 9.6, 1.6 Hz, 1H), 4.15 (s, 2H), 1.25 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 210.0, 162.2, 149.8, 130.8, 126.4, 121.4, 116.3, 44.6, 37.1, 26.3; HRMS (ESI) calcd for C₁₂H₁₅ClN₃O (M+H)⁺ 252.0899, found 252.0897.

3,3-dimethyl-1-(6-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)butan-2-one (3i)




42.8 mg, 75%, yellow solid, m. p. 70-72 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.90 (s, 1H), 7.82 (d, *J* = 8.0 Hz, 1H), 7.67 (d, *J* = 9.2 Hz, 1H), 4.22 (s, 2H), 1.30 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 209.9, 163.7, 151.9, 127.1 (q, *J* = 9.2 Hz), 125.7 (q, *J* = 3.0 Hz), 123.0 (q, *J* = 271.0 Hz), 118.0 (q, *J* = 34.0 Hz), 117.0, 44.8, 37.2, 26.4; HRMS (ESI) calcd for C₁₃H₁₅F₃N₃O (M+H)⁺ 286.1162, found 286.1163.

3,3-dimethyl-1-(5-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)butan-2-one (3j)




33.1 mg, 72%, yellow solid, m. p. 46-48 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.55 (d, J = 8.0 Hz, 1H), 7.40-7.36 (m, 1H), 6.78 (d, J = 7.2 Hz, 1H), 4.19 (s, 2H), 2.75 (s, 3H), 1.27 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 210.4, 160.8, 151.5, 138.5, 129.2, 113.4, 112.6, 44.54, 37.4, 26.4, 17.6; HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{18}\text{N}_3\text{O}$ ($\text{M}+\text{H}$) $^+$ 232.1445, found 232.1445.

1-(5-chloro-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-3,3-dimethylbutan-2-one (3k)




38.0 mg, 76%, yellow solid, m. p. 50-52 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.64 (d, J = 8.0 Hz, 1H), 7.47-7.43 (m, 1H), 7.08 (d, J = 8.0 Hz, 1H), 4.23 (s, 2H), 1.27 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 209.9, 161.6, 152.4, 129.6, 129.3, 114.5, 113.5, 44.6, 37.2, 26.4; HRMS (ESI) calcd for $\text{C}_{12}\text{H}_{15}\text{ClN}_3\text{O}$ ($\text{M}+\text{H}$) $^+$ 252.0899, found 252.0899.

3,3-dimethyl-1-(5-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)butan-2-one (3l)




39.9 mg, 70%, yellow solid, m. p. 57-59 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.91 (d, J = 12.0 Hz, 1H), 7.60-7.56 (m, 1H), 7.42 (d, J = 8.0 Hz, 1H), 4.26 (s, 2H), 1.29 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 209.9, 162.5, 152.0, 128.4 (d, J = 37.0 Hz), 128, 120.1, 119.6 (d, J = 276 Hz), 112.9 (d, J = 5.0 Hz), 44.8, 37.2, 26.4; HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{15}\text{F}_3\text{N}_3\text{O}$ ($\text{M}+\text{H}$) $^+$ 286.1162, found 286.1163.

N-([1,2,4]triazolo[1,5-a]pyridin-2-yl)benzamide (3aa)




31.8 mg, 67%, white solid, m. p. 74-76 °C; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.20 (s, 1H), 8.90 (d, J = 6.8 Hz, 1H), 8.02 (d, J = 7.2 Hz, 2H), 7.77-7.73 (m, 1H), 7.68-7.60 (m, 2H), 7.55-7.51 (m, 2H), 7.19-7.15 (m, 1H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 165.2, 158.6, 149.5, 133.8, 132.1, 130.5, 128.9, 128.5, 128.1, 114.9, 113.8; HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{11}\text{N}_4\text{O}$ ($\text{M}+\text{H}$) $^+$ 239.0928, found 239.0927.

N-([1,2,4]triazolo[1,5-a]pyridin-2-yl)-4-methylbenzamide (3ba)




34.8 mg, 69%, white solid, m. p. 92-95 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.10 (s, 1H), 8.90 (d, *J* = 6.8 Hz, 1H), 7.94 (d, *J* = 8.0 Hz, 2H), 7.74-7.63 (m, 2H), 7.32 (d, *J* = 7.6 Hz, 2H), 7.17-7.14 (m, 1H), 2.37 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 164.9, 158.7, 149.4, 142.1, 130.9, 130.3, 128.9, 128.8, 128.1, 114.8, 113.7, 39.5, 21.0; HRMS (ESI) calcd for C₁₄H₁₃N₄O (M+H)⁺ 253.1084, found 253.1082.

***N*-([1,2,4]triazolo[1,5-*a*]pyridin-2-yl)-2-methylbenzamide (3ca)**




31.2 mg, 62%, white solid, m. p. 67-70 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.22 (s, 1H), 8.98 (d, *J* = 8.0 Hz, 1H), 7.82-7.72 (m, 2H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.50-7.47 (m, 1H), 7.40-7.36 (m, 2H), 7.27-7.23 (m, 1H), 2.49 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 167.3, 158.4, 149.4, 136.1, 135.6, 130.6, 130.4, 130.0, 128.8, 127.5, 125.6, 114.8, 113.7, 19.4; HRMS (ESI) calcd for C₁₄H₁₃N₄O (M+H)⁺ 253.1084, found 253.1082.

***N*-([1,2,4]triazolo[1,5-*a*]pyridin-2-yl)-4-methoxybenzamide (3da)**




30.6 mg, 57%, white solid, m. p. 102-105 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.52 (s, 1H), 8.39 (d, *J* = 6.8 Hz, 1H), 7.53 (d, *J* = 8.8 Hz, 2H), 7.23-7.13 (m, 2H), 6.67-7.64 (m, 1H), 6.55 (d, *J* = 8.0 Hz, 2H), 3.34 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 164.4, 162.3, 158.8, 149.5, 130.3, 130.1, 128.8, 125.8, 114.8, 113.7, 55.5, 42.1; HRMS (ESI) calcd for C₁₄H₁₃N₄O₂ (M+H)⁺ 269.1034, found 269.2034.

***N*-([1,2,4]triazolo[1,5-*a*]pyridin-2-yl)-4-bromobenzamide (3ea)**



37.2 mg, 59%, yellow solid, m. p. 87-89 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.30 (s, 1H), 8.90 (d, *J* = 6.8 Hz, 1H), 7.95 (d, *J* = 8.4 Hz, 2H), 7.74 (d, *J* = 8.8 Hz, 3H), 7.69-7.65 (m, 1H), 7.19-7.16 (m, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 164.2, 158.5, 149.5, 132.9, 131.5, 130.5, 130.2, 128.9, 125.9, 114.9, 113.8; HRMS (ESI) calcd for C₁₃H₁₀BrN₄O (M+H)⁺ 317.0033, found 317.0033.


***N*-(7-methoxy-[1,2,4]triazolo[1,5-*a*]pyridin-2-yl)benzamide (3ab)**



37.5 mg, 70%, white solid, m. p. 92-95 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.08 (s, 1H), 8.72 (d, *J* = 7.2 Hz, 1H), 8.01 (d, *J* = 7.6 Hz, 2H), 7.62-7.50 (m, 3H), 7.11 (d, *J* = 2.0 Hz, 1H), 6.80 (dd,


$J = 7.2, 2.4$ Hz, 1H), 3.90 (s, 3H); ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$) δ 165.0, 160.9, 158.9, 151.1, 133.8, 132.0, 129.1, 128.4, 128.0, 106.9, 93.6, 56.2; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{13}\text{N}_4\text{O}_2$ ($\text{M}+\text{H}$) $^+$ 269.1034, found 269.2034.

***N*-(7-chloro-[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzamide (3ac)**




35.4 mg, 65%, yellow solid, m. p. 91-93 °C; ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 11.29 (s, 1H), 8.95 (s, 1H), 8.02-7.96 (m, 3H), 7.63-7.51 (m, 3H), 7.26-7.24 (m, 1H); ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$) δ 164.9, 159.5, 149.7, 135.4, 133.6, 132.1, 129.8, 128.4, 128.1, 114.6, 113.9; HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{10}\text{ClN}_4\text{O}$ ($\text{M}+\text{H}$) $^+$ 273.0538, found 273.0539.

***N*-(7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzamide (3ad)**




44.1 mg, 72%, yellow solid, m. p. 118-112 °C ; ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 11.44 (s, 1H), 9.17 (d, $J = 7.2$ Hz, 1H), 8.30 (s, 1H), 8.03 (d, $J = 7.2$ Hz, 2H), 7.64-7.61 (m, 1H), 7.56-7.52 (m, 2H), 7.47 (dd, $J = 7.2, 1.6$ Hz, 1H); ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$) δ 164.9, 160.1, 148.4, 133.6, 132.2, 130.4, 130.17 (q, $J = 34.0$ Hz), 128.4, 128.1, 123.0 (q, $J = 272.0$ Hz), 113.0 (q, $J = 4.0$ Hz), 109.2 (q, $J = 3.0$ Hz); HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{10}\text{F}_3\text{N}_4\text{O}$ ($\text{M}+\text{H}$) $^+$ 307.0802, found 307.0803.

***N*-(6-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzamide (3ae)**




34.3 mg, 68%, white solid, m. p. 63-65 °C; ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 11.12 (s, 1H), 8.73 (s, 1H), 8.02-8.00 (m, 2H), 7.64-7.58 (m, 2H), 7.54-7.50 (m, 3H), 2.36 (s, 3H); ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$) δ 165.1, 158.3, 148.1, 133.8, 132.85, 132.0, 128.4, 128.0, 126.7, 123.5, 114.1, 17.3; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{13}\text{N}_4\text{O}$ ($\text{M}+\text{H}$) $^+$ 253.1084, found 253.1083.

***N*-(6-chloro-[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzamide (3af)**




33.3 mg, 63%, yellow solid, m. p. 67-70 °C; ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 11.45 (s, 1H), 9.63 (d, $J = 1.2$ Hz, 1H), 8.04 (d, $J = 8.0$ Hz, 2H), 7.93 (d, $J = 1.2$ Hz, 2H), 7.64-7.60 (m, 1H), 7.55-7.51 (m, 2H); ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$) δ 165.0, 159.3, 148.3, 133.7, 132.1, 131.3, 128.4, 128.1, 127.4, 120.1, 115.4; HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{10}\text{ClN}_4\text{O}$ ($\text{M}+\text{H}$) $^+$ 273.0538, found 273.0538.

***N*-(6-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzamide (3ag)**




43.5 mg, 71%, yellow solid, m. p. 79-81 °C; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.29 (s, 1H), 9.30 (s, 1H), 8.01 (d, $J = 7.2$ Hz, 2H), 7.80-7.72 (m, 2H), 7.63-7.59 (m, 1H), 7.55-7.51 (m, 2H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 165.0, 160.4, 150.4, 133.6, 132.20, 128.6 (q, $J = 5.0$ Hz), 128.4, 128.2, 126.3 (q, $J = 8.0$ Hz), 122.4 (q, $J = 270.0$ Hz), 116.0 (q, $J = 34.0$ Hz), 115.7; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{10}\text{F}_3\text{N}_4\text{O}$ ($\text{M}+\text{H}$) $^+$ 307.0802, found 307.0801.

***N*-(5-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzamide (3ah)**




32.3 mg, 64%, white solid, m. p. 74-76 °C; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.19 (s, 1H), 8.04 (d, $J = 8.0$ Hz, 2H), 7.62-7.50 (m, 5H), 7.04 (d, $J = 8.0$ Hz, 1H), 2.71 (s, 3H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 165.1, 158.3, 148.1, 133.8, 132.85, 132.0, 128.4, 128.0, 126.7, 123.5, 114.1, 17.3; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{13}\text{N}_4\text{O}$ ($\text{M}+\text{H}$) $^+$ 253.1084, found 253.1083.

***N*-(5-chloro-[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzamide (3ai)**




29.7 mg, 59%, yellow solid, m. p. 59-61 °C; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.38 (s, 1H), 8.05-8.03 (m, 2H), 7.76 (dd, $J = 8.8, 0.8$ Hz, 1H), 7.69-7.65 (m, 1H), 7.54-7.51 (m, 2H), 7.43-7.41 (m, 1H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 165.1, 158.6, 150.8, 133.6, 132.2, 130.8, 128.4, 128.1, 114.0, 113.6; HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{10}\text{ClN}_4\text{O}$ ($\text{M}+\text{H}$) $^+$ 273.0538, found 273.0538.

***N*-(5-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzamide (3aj)**




40.9 mg, 67%, yellow solid, m. p. 66-68 °C; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.45 (s, 1H), 8.11-8.04 (m, 3H), 7.83-7.74 (m, 2H), 7.62-7.59 (m, 1H), 7.54-7.50 (m, 2H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 165.2, 159.4, 150.5, 133.5, 132.2, 129.6, 128.4, 128.2, 126.4 (q, $J = 37.0$ Hz), 119.8 (q, $J = 275.0$ Hz), 119.7, 114.0 (q, $J = 4.0$ Hz); HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{10}\text{F}_3\text{N}_4\text{O}$ ($\text{M}+\text{H}$) $^+$ 307.0802, found 307.0801.

***N*-(6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzamide (3ak)**




1.48 g, 47% (10 mmol scale), yellow solid, m. p. 79-81 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.28 (s, 1H), 9.34 (d, *J* = 1.2 Hz, 1H), 8.01 (d, *J* = 7.2 Hz, 2H), 7.82-7.80 (m, 1H), 7.63-7.59 (m, 1H), 7.55-7.51 (m, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 164.9, 159.1, 148.4, 133.7, 133.5, 132.1, 129.3, 128.4, 128.1, 115.7, 106.8; HRMS (ESI) calcd for C₁₃H₁₀BrN₄O (M+H)⁺ 317.0033, found 317.0032.

***N*-(6-(*m*-tolyl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-yl)benzamide (5)**




56.4 mg, 86%, yellow solid, m. p. 77-80 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.24 (s, 1H), 9.24 (s, 1H), 8.04-8.00 (m, 3H), 7.80 (d, *J* = 12.0 Hz, 1H), 7.64-7.52 (m, 5H), 7.42-7.38 (m, 1H), 7.24 (d, *J* = 8.0 Hz, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 165.0, 159.0, 148.7, 138.4, 132.1, 130.0, 129.0, 128.7, 128.4, 128.1, 127.5, 125.8, 124.0, 114.7, 21.1; HRMS (ESI) calcd for C₂₀H₁₆N₄O (M+H)⁺ 329.1357, found 329.1355.

3-cyclopentyl-*N*-(6-(*m*-tolyl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-yl)propanamide (6)



53.3 mg, 67% (two steps from 5), white solid, m. p. 89-91 °C ; ¹H NMR (400 MHz, CDCl₃) δ 9.84 (s, 1H), 8.81 (s, 1H), 7.76 (dd, *J* = 23.6, 9.2 Hz, 2H), 7.42-7.34 (m, 3H), 7.28-7.23 (m, 1H), 2.76-2.46 (m, 4H), 1.90-1.79 (m, 6H), 1.63-1.53 (m, 4H), 1.24-1.07 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 139.1, 136.1, 130.6, 129.1, 128.1, 127.6, 125.7, 124.0, 114.6, 39.7, 32.5, 31.3, 25.1, 21.5; HRMS (ESI) calcd for C₂₁H₂₅N₄O (M+H)⁺, 349.2023 found 349.2023.

5-(*tert*-butyl)-*N*-(pyridin-2-yl)isoxazol-3-amine (7)



17.8 mg, 41%, yellow solid, m. p. 39-41 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.45 (s, 1H), 8.27-8.23 (m, 1H), 7.66-7.61 (m, 1H), 7.51 (d, *J* = 8.4 Hz, 1H), 6.88-6.85 (m, 1H), 6.11 (s, 1H), 1.35 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 180.4, 159.7, 153.7, 147.7, 138.3, 116.4, 111.1, 92.1, 32.8, 28.7. HRMS calcd for C₁₂H₁₆N₃O (M+H)⁺ 218.1288, found 218.1289.

